Soligenix (SNGX) Reports Second Quarter Financials and Highlights Accomplishments
Soligenix, a development stage biopharmaceutical company, announced second quarter revenues of $762,851 as compared to $405,820 reported for second quarter of 2011. The revenue increase is related to increased reimbursable costs from the Company's ThermoVax™, Thermostability Technology Grant focused on a novel method of rendering aluminum salt adjuvanted vaccines stable at elevated temperatures. The company recently announced the receipt of the Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases to further support preclinical development of OrbeShield™ as a treatment for gastrointestinal acute radiation syndrome. Soligenix also announced a collaboration with the Infectious Disease Research…